StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
105
This year
12
Publishing Date
2024 - 02 - 23
3
2024 - 02 - 16
2
2024 - 02 - 02
1
2024 - 01 - 26
2
2024 - 01 - 25
2
2024 - 01 - 16
1
2023 - 11 - 29
1
2023 - 11 - 27
3
2023 - 10 - 23
2
2023 - 10 - 22
2
2023 - 10 - 20
1
2023 - 09 - 26
2
2023 - 05 - 22
1
2023 - 05 - 21
2
2023 - 05 - 04
1
2023 - 04 - 04
1
2023 - 03 - 23
3
2023 - 03 - 21
2
2023 - 03 - 18
2
2023 - 03 - 07
2
2023 - 02 - 21
1
2023 - 01 - 30
2
2023 - 01 - 27
2
2022 - 12 - 21
2
2022 - 12 - 16
2
2022 - 12 - 15
2
2022 - 11 - 11
1
2022 - 10 - 11
3
2022 - 09 - 28
2
2022 - 09 - 26
1
2022 - 09 - 15
1
2022 - 09 - 09
1
2022 - 09 - 08
2
2022 - 09 - 05
2
2022 - 08 - 03
1
2022 - 07 - 28
4
2022 - 07 - 14
5
2022 - 06 - 16
1
2022 - 06 - 08
1
2022 - 06 - 07
2
2022 - 05 - 31
2
2022 - 05 - 20
2
2022 - 04 - 28
1
2022 - 04 - 07
2
2022 - 04 - 04
2
2022 - 03 - 29
1
2022 - 03 - 28
1
2022 - 03 - 26
2
2022 - 03 - 01
1
2022 - 02 - 26
2
2022 - 02 - 18
3
2022 - 02 - 10
1
2022 - 02 - 02
1
2022 - 01 - 31
1
2022 - 01 - 19
2
2021 - 12 - 13
1
2021 - 12 - 08
1
2021 - 10 - 25
2
2021 - 10 - 22
1
2021 - 10 - 20
1
Sector
Health technology
105
Tags
Acquisition
80
Alliances
71
America
64
Antibody
48
Approval
63
Approved
41
Biopharma
81
Biotech
49
Biotechnology
105
Business
80
Cancer
165
Children
61
Clinical-trials-phase-ii
42
Clinical-trials-phase-iii
67
Collaboration
80
Companies
59
Conference
48
Covid
43
Covid-19
75
Deal
50
Disease
130
Drug
173
Dupixent
105
Earnings
72
Europe
72
Events
54
Expected
44
Fda
204
Fda-approvals
43
Financial
163
Genetown
59
Global
356
Growing
50
Growth
280
Health
67
Market
711
Money
58
N/a
2233
News
98
People
161
Pharm-country
42
Pharma
145
Pharmaceutical
120
Positive
79
Potential
59
Reach
50
Regulatory
55
Report
307
Research
233
Results
291
Sanofi
199
Spac
46
Study
86
Therapeutics
320
Therapy
79
Treatment
229
Trial
120
Update
91
Vaccine
163
Year
61
Entities
Abbott laboratories
2
Eli lilly and company
4
Johnson & johnson
4
Perrigo company
4
Regeneron pharmaceuticals, inc.
72
Sanofi
105
Teva pharmaceutical industries ltd
34
Symbols
ABBV
2
ABT
2
JNJ
4
LLY
4
PRGO
4
REGN
80
SNY
118
SNYNF
105
TEVJF
34
Exchanges
Nasdaq
105
Nyse
8
Crawled Date
2024 - 02 - 23
3
2024 - 02 - 16
2
2024 - 02 - 02
1
2024 - 01 - 26
2
2024 - 01 - 25
2
2024 - 01 - 16
1
2023 - 11 - 29
1
2023 - 11 - 27
3
2023 - 10 - 23
2
2023 - 10 - 22
2
2023 - 10 - 20
1
2023 - 09 - 26
2
2023 - 05 - 22
1
2023 - 05 - 21
2
2023 - 05 - 04
1
2023 - 04 - 04
1
2023 - 03 - 23
3
2023 - 03 - 21
2
2023 - 03 - 18
2
2023 - 03 - 07
2
2023 - 02 - 21
1
2023 - 01 - 30
2
2023 - 01 - 27
2
2022 - 12 - 21
2
2022 - 12 - 16
2
2022 - 12 - 15
2
2022 - 11 - 11
1
2022 - 10 - 11
3
2022 - 09 - 28
2
2022 - 09 - 26
1
2022 - 09 - 15
1
2022 - 09 - 09
1
2022 - 09 - 08
2
2022 - 09 - 05
2
2022 - 08 - 03
1
2022 - 07 - 28
4
2022 - 07 - 14
5
2022 - 06 - 16
1
2022 - 06 - 08
1
2022 - 06 - 07
2
2022 - 05 - 31
2
2022 - 05 - 20
2
2022 - 04 - 28
1
2022 - 04 - 07
2
2022 - 04 - 04
2
2022 - 03 - 29
1
2022 - 03 - 28
1
2022 - 03 - 26
2
2022 - 03 - 01
1
2022 - 02 - 26
2
2022 - 02 - 18
3
2022 - 02 - 10
1
2022 - 02 - 02
1
2022 - 01 - 31
1
2022 - 01 - 19
2
2021 - 12 - 13
1
2021 - 12 - 08
1
2021 - 10 - 25
2
2021 - 10 - 22
1
2021 - 10 - 20
1
Crawled Time
01:00
1
02:00
1
05:00
2
06:00
15
07:00
11
08:00
7
09:00
2
11:00
1
12:00
3
12:20
2
13:00
2
14:00
2
14:15
1
14:20
3
14:30
3
15:00
8
15:20
1
15:30
1
16:00
6
16:20
4
17:00
3
18:00
4
20:00
4
20:20
6
21:00
3
22:00
4
23:00
5
Source
www.biospace.com
44
www.globenewswire.com
41
www.prnewswire.com
20
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Dupixent
symbols :
Snynf
save search
Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Published:
2024-03-11
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-3.66%
|
O:
0.57%
H:
0.0%
C:
0.0%
disease
dupixent
skin
Sanofi, Regeneron Secure FDA Priority Review for Dupixent in COPD
Published:
2024-02-23
(Crawled : 15:00)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-3.37%
|
O:
0.97%
H:
0.0%
C:
0.0%
fda
dupixent
review
copd
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published:
2024-02-23
(Crawled : 06:00)
- globenewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-3.37%
|
O:
0.97%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-7.05%
|
O:
1.05%
H:
1.09%
C:
0.64%
dupixent
fda
review
treatment
copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published:
2024-02-23
(Crawled : 06:00)
- globenewswire.com
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-3.37%
|
O:
0.97%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-7.05%
|
O:
1.05%
H:
1.09%
C:
0.64%
dupixent
fda
review
treatment
copd
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Published:
2024-02-16
(Crawled : 06:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
0.42%
|
O:
1.66%
H:
0.0%
C:
-1.59%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-0.45%
|
O:
-0.6%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-6.07%
|
O:
-0.14%
H:
0.32%
C:
-0.57%
dupixent
first
japan
urticaria
world
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Published:
2024-02-16
(Crawled : 06:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
0.42%
|
O:
1.66%
H:
0.0%
C:
-1.59%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-0.45%
|
O:
-0.6%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-6.07%
|
O:
-0.14%
H:
0.32%
C:
-0.57%
dupixent
first
japan
urticaria
world
FDA Decisions: Sanofi/Regeneron's Dupixent Racks Up Another Pediatric Indication
Published:
2024-02-02
(Crawled : 15:00)
- biospace.com/
PRGO
|
News
|
$30.8
2.87%
-1.14%
1.2M
|
Health Technology
|
-4.58%
|
O:
-0.53%
H:
1.28%
C:
0.53%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-6.43%
|
O:
-0.15%
H:
0.0%
C:
0.0%
ABT
|
News
|
$107.28
1.91%
0.18%
10M
|
Health Technology
|
-6.3%
|
O:
-0.57%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.46%
|
O:
-0.93%
H:
0.0%
C:
0.0%
fda
dupixent
Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Published:
2024-01-26
(Crawled : 15:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-7.21%
|
O:
0.5%
H:
0.0%
C:
0.0%
label
dupixent
treat
expansion
FDA Decisions: Sanofi/Regeneron's Dupixent Racks Up Another Pediatric Indication
Published:
2024-01-26
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
PRGO
|
News
|
$30.8
2.87%
-1.14%
1.2M
|
Health Technology
|
-7.0%
|
O:
0.72%
H:
0.45%
C:
0.24%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-7.03%
|
O:
0.8%
H:
0.0%
C:
0.0%
ABT
|
News
|
$107.28
1.91%
0.18%
10M
|
Health Technology
|
-4.6%
|
O:
0.68%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-7.21%
|
O:
0.5%
H:
0.0%
C:
0.0%
fda
dupixent
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published:
2024-01-25
(Crawled : 20:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-7.21%
|
O:
0.5%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-5.49%
|
O:
0.33%
H:
0.65%
C:
-1.26%
dupixent
fda
first
children
approved
year
treatment
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published:
2024-01-25
(Crawled : 20:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.6%
|
O:
1.8%
H:
0.0%
C:
-1.82%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-7.21%
|
O:
0.5%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-5.49%
|
O:
0.33%
H:
0.65%
C:
-1.26%
dupixent
fda
first
children
approved
year
treatment
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
Published:
2024-01-16
(Crawled : 12:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-12.55%
|
O:
-2.03%
H:
0.05%
C:
0.05%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.59%
|
O:
-1.34%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
-3.9%
|
O:
-0.21%
H:
0.67%
C:
0.66%
dupixent
label
dermatitis
Deals, Dupixent and GLP-1 drug shortages
Published:
2023-11-29
(Crawled : 15:30)
- biospace.com/
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.45%
|
O:
-0.15%
H:
0.07%
C:
-0.66%
drug
dupixent
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published:
2023-11-27
(Crawled : 17:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.72%
|
O:
1.04%
H:
0.17%
C:
0.11%
dupixent
positive
copd
results
sanofi
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published:
2023-11-27
(Crawled : 07:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.72%
|
O:
1.04%
H:
0.17%
C:
0.11%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
12.34%
|
O:
0.46%
H:
0.37%
C:
-0.49%
dupixent
fda
disease
approved
positive
copd
potential
submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published:
2023-11-27
(Crawled : 07:00)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-2.62%
|
O:
-0.36%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-1.72%
|
O:
1.04%
H:
0.17%
C:
0.11%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
12.34%
|
O:
0.46%
H:
0.37%
C:
-0.49%
dupixent
fda
disease
approved
positive
copd
potential
submission
BioMarin Scores Expanded Approval for Dwarfism Treatment; Dupixent Suffers Ra...
Published:
2023-10-23
(Crawled : 15:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-10.22%
|
O:
0.73%
H:
0.0%
C:
-0.48%
PRGO
|
News
|
$30.8
2.87%
-1.14%
1.2M
|
Health Technology
|
3.25%
|
O:
-0.44%
H:
0.08%
C:
-2.05%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-2.9%
|
O:
0.28%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.56%
|
O:
-0.69%
H:
0.0%
C:
0.0%
dupixent
approval
BioMarin Scores Expanded Approval for Dwarfism Treatment; Dupixent Suffers Rare Defeat
Published:
2023-10-23
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-10.22%
|
O:
0.73%
H:
0.0%
C:
-0.48%
PRGO
|
News
|
$30.8
2.87%
-1.14%
1.2M
|
Health Technology
|
3.25%
|
O:
-0.44%
H:
0.08%
C:
-2.05%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-2.9%
|
O:
0.28%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.56%
|
O:
-0.69%
H:
0.0%
C:
0.0%
rare
dupixent
approval
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published:
2023-10-22
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-10.22%
|
O:
0.73%
H:
0.0%
C:
-0.48%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.56%
|
O:
-0.69%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
10.93%
|
O:
0.21%
H:
0.08%
C:
-1.81%
dupixent
children
year
one
results
show
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Published:
2023-10-22
(Crawled : 20:20)
- globenewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-10.22%
|
O:
0.73%
H:
0.0%
C:
-0.48%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-11.56%
|
O:
-0.69%
H:
0.0%
C:
0.0%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
10.93%
|
O:
0.21%
H:
0.08%
C:
-1.81%
dupixent
children
year
one
results
show
← Previous
1
2
3
4
5
6
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.